An FDA advisory committee on Thursday said the confirmatory trial data for the KRAS inhibitor sotorasib (Lumakras) in previously treated non-small cell lung cancer (NSCLC) cannot be reliably ...
CodeBreaK 200, the global Phase 3 randomized active-controlled study comparing sotorasib to docetaxel in KRAS G12C-mutated NSCLC completed enrollment of 345 patients. Eligible patients had previously ...
Amgen Inc. AMGN announced top-line data from the phase III CodeBreaK 200 study, which evaluated its KRAS inhibitor, Lumakras (sotorasib), for the treatment of non-small cell lung cancer (NSCLC). The ...
In the first and only randomized study for any KRASG12C inhibitor, data from a post-hoc analysis of the global Phase 3 CodeBreaK 200 trial included patients with advanced NSCLC and treated/stable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback